YJ Liu, director of Clinical Cytogenomics Lab, publishes in Cancer Genetics on use of microarray in dedifferentiated liposarcoma

Yajuan J. Liu, PhD, director of the Center For Precision Diagnostics’ Clinical Cytogenomics Laboratory, is the last author on a paper recently published in Cancer Genetics:  “High amplification levels of MDM2 and CDK4 correlate with poor outcome in patients with dedifferentiated liposarcoma:  A cytogenomic microarray analysis of 47 cases.”  The work was done in collaboration with colleagues in the University of Washington Departments of BioStatistics and Laboratory Medicine, Anderson Cancer Center, Prevention Genetics, and Hebei University (China).  The goal was to use cytogenomic microarray analysis (CMA) to identify genomic abnormalities that correlate with survival, as a way to stratify the risk faced by people diagnosed with dedifferentiated liposarcomas (DDLS).  Forty-seven patients with DDLS were identified, and CMA was performed on archived tumor samples.  Liu and colleagues found that increased copy number of the MDM2 and CDK4 genes is strongly correlated with decreased survival (poorer prognosis).  They also saw a synergistic effect, in that amplification of one of these genes increases the poor prognostic effect that each additional copy of the other gene has.  Increased copy number for the JUN gene may also be correlated with poorer prognosis.